Drug Profile

YOLT 202

Alternative Names: YOLT-202

Latest Information Update: 25 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator YolTech Therapeutics
Class Gene therapies
Mechanism of Action Gene expression modulators; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alpha 1-antitrypsin deficiency
New Molecular Entity No

Highest Development Phases

Phase 0 Alpha 1-antitrypsin deficiency

Most Recent Events

14 Mar 2026 The US FDA approves IND application for YOLT 202 in Alpha 1-antitrypsin deficiency
14 Mar 2026 YolTech Therapeutics plans a phase II/III trial for Alpha 1-antitrypsin deficiency in USA and other countries
19 Feb 2026 YolTech Therapeutics announces intention to submit IND to US FDA for Alpha 1-antitrypsin deficiency

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com